Kay Limoli

1.6k total citations · 1 hit paper
14 papers, 1.2k citations indexed

About

Kay Limoli is a scholar working on Infectious Diseases, Virology and Immunology. According to data from OpenAlex, Kay Limoli has authored 14 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 11 papers in Virology and 4 papers in Immunology. Recurrent topics in Kay Limoli's work include HIV Research and Treatment (11 papers), HIV/AIDS drug development and treatment (11 papers) and HIV/AIDS Research and Interventions (5 papers). Kay Limoli is often cited by papers focused on HIV Research and Treatment (11 papers), HIV/AIDS drug development and treatment (11 papers) and HIV/AIDS Research and Interventions (5 papers). Kay Limoli collaborates with scholars based in United States, Switzerland and Germany. Kay Limoli's co-authors include Christos J. Petropoulos, Wei Huang, Jeannette M. Whitcomb, Terri Wrin, Neil Parkin, Genine Winslow, Huan Tian, Yolanda Lie, Daniel J. Capon and Ellen E. Paxinos and has published in prestigious journals such as PLoS ONE, Journal of Virology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Kay Limoli

13 papers receiving 1.2k citations

Hit Papers

A Novel Phenotypic Drug Susceptibility Assay for Human Im... 2000 2026 2008 2017 2000 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
    2000 525 citations Christos J. Petropoulos, Neil Parkin et al. Antimicrobial Agents and Chemotherapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kay Limoli United States 12 1.1k 1.1k 165 152 111 14 1.2k
Signe Fransen United States 15 997 0.9× 876 0.8× 277 1.7× 163 1.1× 144 1.3× 25 1.1k
Elly Baan Netherlands 15 768 0.7× 533 0.5× 115 0.7× 142 0.9× 239 2.2× 21 859
Roberta D’Arrigo Italy 20 735 0.7× 717 0.7× 261 1.6× 160 1.1× 75 0.7× 37 957
Jonathan Toma United States 13 778 0.7× 566 0.5× 175 1.1× 149 1.0× 228 2.1× 21 865
M. B. Vasudevachari United States 12 693 0.6× 550 0.5× 126 0.8× 196 1.3× 140 1.3× 21 861
Marilyn Lewis United Kingdom 14 1.0k 0.9× 803 0.8× 255 1.5× 265 1.7× 243 2.2× 25 1.2k
Conan K. Woods Canada 14 875 0.8× 809 0.8× 136 0.8× 354 2.3× 76 0.7× 25 1.1k
Dorien de Jong Netherlands 13 790 0.7× 779 0.7× 101 0.6× 95 0.6× 44 0.4× 23 902
Luke C. Swenson Canada 17 690 0.6× 585 0.5× 172 1.0× 144 0.9× 84 0.8× 35 834
C. Petropoulos United States 11 626 0.6× 555 0.5× 138 0.8× 95 0.6× 83 0.7× 17 769

Countries citing papers authored by Kay Limoli

Since Specialization
Citations

This map shows the geographic impact of Kay Limoli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kay Limoli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kay Limoli more than expected).

Fields of papers citing papers by Kay Limoli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kay Limoli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kay Limoli. The network helps show where Kay Limoli may publish in the future.

Co-authorship network of co-authors of Kay Limoli

This figure shows the co-authorship network connecting the top 25 collaborators of Kay Limoli. A scholar is included among the top collaborators of Kay Limoli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kay Limoli. Kay Limoli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Mesa, Kathryn A., David L. Alexander, Bin Yu, et al.. (2019). Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies. Frontiers in Immunology. 10. 1021–1021. 6 indexed citations
2.
O’Rourke, Sara M., Ruengpung Sutthent, Pham Phung, et al.. (2015). Glycans Flanking the Hypervariable Connecting Peptide between the A and B Strands of the V1/V2 Domain of HIV-1 gp120 Confer Resistance to Antibodies That Neutralize CRF01_AE Viruses. PLoS ONE. 10(3). e0119608–e0119608. 13 indexed citations
3.
Narayan, Kristin, Daniel P. Leaman, Pham Phung, et al.. (2013). Prime-Boost Immunization of Rabbits with HIV-1 gp120 Elicits Potent Neutralization Activity against a Primary Viral Isolate. PLoS ONE. 8(1). e52732–e52732. 14 indexed citations
4.
Acosta, Edward P., Kay Limoli, Lan Trinh, et al.. (2012). Novel Method To Assess Antiretroviral Target Trough Concentrations UsingIn VitroSusceptibility Data. Antimicrobial Agents and Chemotherapy. 56(11). 5938–5945. 35 indexed citations
5.
O’Rourke, Sara M., Becky Schweighardt, Pham Phung, et al.. (2012). Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies. Journal of Virology. 86(22). 12105–12114. 24 indexed citations
6.
Lin, Kai, et al.. (2010). Telbivudine Exhibits No Inhibitory Activity against HIV-1 Clinical Isolates In Vitro. Antimicrobial Agents and Chemotherapy. 54(6). 2670–2673. 12 indexed citations
7.
Whitcomb, Jeannette M., Wei Huang, Signe Fransen, et al.. (2006). Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism. Antimicrobial Agents and Chemotherapy. 51(2). 566–575. 268 indexed citations
8.
Colonno, Richard J., Alexandra Thiry, Kay Limoli, & Neil Parkin. (2003). Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors. Antimicrobial Agents and Chemotherapy. 47(4). 1324–1333. 80 indexed citations
9.
Whitcomb, Jeannette M., Wei Huang, Kay Limoli, et al.. (2002). Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1. AIDS. 16(15). F41–F47. 69 indexed citations
10.
Huang, Wei, Andrea V. Gamarnik, Kay Limoli, Christos J. Petropoulos, & Jeannette M. Whitcomb. (2002). Amino Acid Substitutions at Position 190 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Increase Susceptibility to Delavirdine and Impair Virus Replication. Journal of Virology. 77(2). 1512–1523. 76 indexed citations
11.
Ziermann, Rainer, Kay Limoli, Kalyan Das, et al.. (2000). A Mutation in Human Immunodeficiency Virus Type 1 Protease, N88S, That Causes In Vitro Hypersensitivity to Amprenavir. Journal of Virology. 74(9). 4414–4419. 69 indexed citations
12.
Petropoulos, Christos J., Neil Parkin, Kay Limoli, et al.. (2000). A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy. 44(4). 920–928. 525 indexed citations breakdown →
13.
Farson, Deborah, Ryan McGuinness, Kay Limoli, et al.. (1999). Large‐scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols. The Journal of Gene Medicine. 1(3). 195–209. 23 indexed citations
14.
Farson, Deborah, Ryan McGuinness, Kay Limoli, et al.. (1999). Large‐scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols. The Journal of Gene Medicine. 1(3). 195–209.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Signe Fransen Breakdown of academic impact, for papers by Elly Baan Breakdown of academic impact, for papers by Roberta D’Arrigo Breakdown of academic impact, for papers by Jonathan Toma Breakdown of academic impact, for papers by M. B. Vasudevachari Breakdown of academic impact, for papers by Marilyn Lewis Breakdown of academic impact, for papers by Conan K. Woods Breakdown of academic impact, for papers by Dorien de Jong Breakdown of academic impact, for papers by Luke C. Swenson Breakdown of academic impact, for papers by C. Petropoulos
Rankless by CCL
2026